Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomised, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of Ambrisentan in Patients With Severe COVID-19

NCT04771000 is registered in ClinicalTrials.gov with Noorik Biopharmaceuticals AG as lead sponsor.

NCT NCT04771000
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04771000 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomised, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of Ambrisentan in Patients With Severe COVID-19
Lead sponsor
Noorik Biopharmaceuticals AG
Phase
Phase 2
Overall status
Terminated
Start date
February 8, 2021
Completion date
February 27, 2023
Enrollment
88 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

covid19, hypoxemia